Sunitinib in advanced metastatic non-clear cell renal cell carcinoma: A single institution retrospective study

Chiara Paglino, Ilaria Imarisio, Carlo Ganini, Patrizia Morbini, Alessandro Vercelli, Cristina Bregant, Camillo Porta

Research output: Contribution to journalArticle

Abstract

Aim: Sunitinib is an orally active multi-targeted tyrosine kinase inhibitor that exerts its antitumor effects primarily through the selective inhibition of VEGF. Novel targeted therapies such as sunitinib have transformed the treatment of advanced metastatic renal cell carcinomas, particularly those with clear cell histology. Here, our experience in patients with non-clear cell kidney cancer treated as part of the sunitinib Expanded Access Program is reported. Materials & methods: This was a retrospective assessment of 21 patients with non-clear cell renal cell carcinoma who were treated with oral sunitinib 50 mg/day in repeated 6 weekly cycles (4 weeks on and 2 weeks off). Disease assessment and physical examination were recorded at baseline and tumor assessments were performed every 3 months, according to Response Evaluation Criteria In Solid Tumors. The primary outcome measure was progression-free survival. Results: Patients received an average of 6.38 cycles of sunitinib; one patient was classified as a complete responder and two as partial responders. The overall response rate was 14.3% and clinical benefit was attained by 52.4%. The median progression-free survival was 4.1 months while median overall survival was 14.6 months. In general, sunitinib was well tolerated and only three patients experienced a grade 3 toxicity, which resolved with dosage reduction. Conclusion: As expected, sunitinib exerted lower antitumor activity in patients with non-clear cell renal cell carcinoma than was achieved in the general population with metastatic kidney cancer. However, responses (one complete and two partial) were documented and clinical benefit was observed in more than half of all patients.

Original languageEnglish
Pages (from-to)1605-1612
Number of pages8
JournalFuture Oncology
Volume8
Issue number12
DOIs
Publication statusPublished - Dec 2012

Fingerprint

Retrospective Studies
Renal Cell Carcinoma
Kidney Neoplasms
Disease-Free Survival
sunitinib
Clear-cell metastatic renal cell carcinoma
Protein-Tyrosine Kinases
Vascular Endothelial Growth Factor A
Physical Examination
Histology
Outcome Assessment (Health Care)
Survival
Therapeutics
Population
Neoplasms

Keywords

  • angiogenesis
  • kidney cancer
  • non-clear cell renal cell carcinoma
  • sunitinib
  • vascular endothelial growth factor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Sunitinib in advanced metastatic non-clear cell renal cell carcinoma : A single institution retrospective study. / Paglino, Chiara; Imarisio, Ilaria; Ganini, Carlo; Morbini, Patrizia; Vercelli, Alessandro; Bregant, Cristina; Porta, Camillo.

In: Future Oncology, Vol. 8, No. 12, 12.2012, p. 1605-1612.

Research output: Contribution to journalArticle

@article{506b276d6b38411085ed282986afafbe,
title = "Sunitinib in advanced metastatic non-clear cell renal cell carcinoma: A single institution retrospective study",
abstract = "Aim: Sunitinib is an orally active multi-targeted tyrosine kinase inhibitor that exerts its antitumor effects primarily through the selective inhibition of VEGF. Novel targeted therapies such as sunitinib have transformed the treatment of advanced metastatic renal cell carcinomas, particularly those with clear cell histology. Here, our experience in patients with non-clear cell kidney cancer treated as part of the sunitinib Expanded Access Program is reported. Materials & methods: This was a retrospective assessment of 21 patients with non-clear cell renal cell carcinoma who were treated with oral sunitinib 50 mg/day in repeated 6 weekly cycles (4 weeks on and 2 weeks off). Disease assessment and physical examination were recorded at baseline and tumor assessments were performed every 3 months, according to Response Evaluation Criteria In Solid Tumors. The primary outcome measure was progression-free survival. Results: Patients received an average of 6.38 cycles of sunitinib; one patient was classified as a complete responder and two as partial responders. The overall response rate was 14.3{\%} and clinical benefit was attained by 52.4{\%}. The median progression-free survival was 4.1 months while median overall survival was 14.6 months. In general, sunitinib was well tolerated and only three patients experienced a grade 3 toxicity, which resolved with dosage reduction. Conclusion: As expected, sunitinib exerted lower antitumor activity in patients with non-clear cell renal cell carcinoma than was achieved in the general population with metastatic kidney cancer. However, responses (one complete and two partial) were documented and clinical benefit was observed in more than half of all patients.",
keywords = "angiogenesis, kidney cancer, non-clear cell renal cell carcinoma, sunitinib, vascular endothelial growth factor",
author = "Chiara Paglino and Ilaria Imarisio and Carlo Ganini and Patrizia Morbini and Alessandro Vercelli and Cristina Bregant and Camillo Porta",
year = "2012",
month = "12",
doi = "10.2217/fon.12.145",
language = "English",
volume = "8",
pages = "1605--1612",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "12",

}

TY - JOUR

T1 - Sunitinib in advanced metastatic non-clear cell renal cell carcinoma

T2 - A single institution retrospective study

AU - Paglino, Chiara

AU - Imarisio, Ilaria

AU - Ganini, Carlo

AU - Morbini, Patrizia

AU - Vercelli, Alessandro

AU - Bregant, Cristina

AU - Porta, Camillo

PY - 2012/12

Y1 - 2012/12

N2 - Aim: Sunitinib is an orally active multi-targeted tyrosine kinase inhibitor that exerts its antitumor effects primarily through the selective inhibition of VEGF. Novel targeted therapies such as sunitinib have transformed the treatment of advanced metastatic renal cell carcinomas, particularly those with clear cell histology. Here, our experience in patients with non-clear cell kidney cancer treated as part of the sunitinib Expanded Access Program is reported. Materials & methods: This was a retrospective assessment of 21 patients with non-clear cell renal cell carcinoma who were treated with oral sunitinib 50 mg/day in repeated 6 weekly cycles (4 weeks on and 2 weeks off). Disease assessment and physical examination were recorded at baseline and tumor assessments were performed every 3 months, according to Response Evaluation Criteria In Solid Tumors. The primary outcome measure was progression-free survival. Results: Patients received an average of 6.38 cycles of sunitinib; one patient was classified as a complete responder and two as partial responders. The overall response rate was 14.3% and clinical benefit was attained by 52.4%. The median progression-free survival was 4.1 months while median overall survival was 14.6 months. In general, sunitinib was well tolerated and only three patients experienced a grade 3 toxicity, which resolved with dosage reduction. Conclusion: As expected, sunitinib exerted lower antitumor activity in patients with non-clear cell renal cell carcinoma than was achieved in the general population with metastatic kidney cancer. However, responses (one complete and two partial) were documented and clinical benefit was observed in more than half of all patients.

AB - Aim: Sunitinib is an orally active multi-targeted tyrosine kinase inhibitor that exerts its antitumor effects primarily through the selective inhibition of VEGF. Novel targeted therapies such as sunitinib have transformed the treatment of advanced metastatic renal cell carcinomas, particularly those with clear cell histology. Here, our experience in patients with non-clear cell kidney cancer treated as part of the sunitinib Expanded Access Program is reported. Materials & methods: This was a retrospective assessment of 21 patients with non-clear cell renal cell carcinoma who were treated with oral sunitinib 50 mg/day in repeated 6 weekly cycles (4 weeks on and 2 weeks off). Disease assessment and physical examination were recorded at baseline and tumor assessments were performed every 3 months, according to Response Evaluation Criteria In Solid Tumors. The primary outcome measure was progression-free survival. Results: Patients received an average of 6.38 cycles of sunitinib; one patient was classified as a complete responder and two as partial responders. The overall response rate was 14.3% and clinical benefit was attained by 52.4%. The median progression-free survival was 4.1 months while median overall survival was 14.6 months. In general, sunitinib was well tolerated and only three patients experienced a grade 3 toxicity, which resolved with dosage reduction. Conclusion: As expected, sunitinib exerted lower antitumor activity in patients with non-clear cell renal cell carcinoma than was achieved in the general population with metastatic kidney cancer. However, responses (one complete and two partial) were documented and clinical benefit was observed in more than half of all patients.

KW - angiogenesis

KW - kidney cancer

KW - non-clear cell renal cell carcinoma

KW - sunitinib

KW - vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=84871183458&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871183458&partnerID=8YFLogxK

U2 - 10.2217/fon.12.145

DO - 10.2217/fon.12.145

M3 - Article

C2 - 23231522

AN - SCOPUS:84871183458

VL - 8

SP - 1605

EP - 1612

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 12

ER -